Wells Fargo & Company MN Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wells Fargo & Company MN grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 85.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 331,403 shares of the biopharmaceutical company's stock after acquiring an additional 152,682 shares during the period. Wells Fargo & Company MN owned about 0.21% of TG Therapeutics worth $9,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its position in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC purchased a new stake in shares of TG Therapeutics during the 4th quarter valued at about $75,000. Finally, GAMMA Investing LLC lifted its holdings in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Trading Up 2.6 %

Shares of NASDAQ:TGTX traded up $0.96 during trading on Tuesday, reaching $37.93. 158,979 shares of the company were exchanged, compared to its average volume of 3,094,116. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The firm has a market capitalization of $5.96 billion, a PE ratio of -379.41 and a beta of 2.14. The business's fifty day simple moving average is $36.46 and its 200-day simple moving average is $32.09. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.